Unlock the Power to Transform Lives:

Discover the keys to clinically meaningful weight loss thresholds and revolutionize your approach to tackling obesity complications! In our comprehensive program, esteemed faculty members will delve into cutting-edge presentations, including the use of Anti-Obesity Medications (AOM) for significant weight loss, the resolution of obesity complications, and the integration of combination therapies with SGLT-2, GLP-1, and other groundbreaking therapeutics.

Gain Knowledge That Transforms Practice!

✓ Demystifying misinformation on anti-obesity medications

✓ Diagnosing obesity as a chronic, progressive disease demanding early intervention

✓ Reviewing pharmacotherapy, including AOMs and their indications/contra-indications

✓ Evidence-based recommendations for treating obesity

Embark on a transformative learning experience!

Our program guides learners through a series of activities, progressing from recognizing obesity as a chronic disease in need of intervention to implementing practice changes. Witness the power of knowledge in action as you become a champion in the fight against obesity.

Upon successful completion of the program, participants should be better able to:

• Recognize obesity as a chronic, complex, and progressive disease warranting diagnosis, early intervention, and long-term management.
• Apply evidence-based recommendations for treatment for patients with obesity (encompassing AOMs including GLP-1s, SGLT2 inhibitors, behavioral interventions, and bariatric surgery).
• Identify the appropriate treatment strategies and contraindications for anti-obesity medications for persons with concurrent conditions (e.g., diabetes, cardiovascular disease).

The target audience for this activity is is U.S. healthcare professionals (HCPs), including primary care physicians (PCPs) such as family physicians and internists, physicians-in-training, nurse practitioners (NPs), physician associates (PAs), registered dietitians (RDs), nurses, and other HCPs. 

Physicians and Physician Assistants 
The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American College of Endocrinology (ACE) designates this enduring activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Only those who receive a passing score will be eligible for MOC credit.  

Please allow two weeks for MOC points to appear within your account on the ABIM website. Participation information will be shared.

Nurses 
American Association of Clinical Endocrinology is approved by the California Board of Registered Nursing, Provider Number 17762, for 3.5 contact hours.

This activity is supported by an independent educational grant from Novo Nordisk

The American Association of Clinical Endocrinologists (AACE) remains strongly committed to providing the best available evidence based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflict of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the CME Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities. 

All of the relevant financial relationships listed for these individuals have been mitigated. All other planners and faculty for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.  

Planners

• Mihail Zilbermint, MD, FACE, MBA
  ROM Tech/Shareholder, EMD Serono/Consultant
  
  
• Jennifer Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM
  Novo Nordisk/Speaker's Bureau
  
  
• Elizabeth (Lissa) Bauer, MD, FACP
  
  
• Joanna Miragaya, MD, PhD, FACE
  
  
• Reshmi Srinath, MD
  
  
• Jaime Almandoz, MD
  Novo Nordisk/Consultant, Eli Lilly/Consultant
  
  
• Karla Saint Andre, MD
  Rythm, Novartis, Karyopharm, Pacific, Viatris, Novo, Rockley, Amgen/Stocks
  
  
• Richele Corrado, DO, MPH
  Novo Nordisk, Eli Lilly/Stocks
  
  
• Camille Stanback, MD
  
  
• Elizabeth Milward
  
  
• Diane Alberson
  
  
• Beth Welch
  
  

Faculty

• Jennifer Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM
  Novo Nordisk/Speaker's Bureau
  
  
• Joanna Miragaya, MD, PhD, FACE
  
  
• Karla Saint Andre
  Rythm, Novartis, Karyopharm, Pacific, Viatris, Novo, Rockley, Amgen/Stocks
  
  
• Reshmi Srinath, MD
  
  
• Richele Corrado, DO, MPH
  Novo Nordisk, Eli Lilly/Stocks
  
  
• Camille Stanback, MD

 

https://my.aace.com/NC__Product?id=a1B5a00000qWEvLEAW

FREE

ENDO, PCP, NP, PA